Disease · MONDO_0005563
nut midline carcinoma
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. nut midline carcinoma. Diseases, record MONDO_0005563. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005563
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Midline carcinoma of children and Young adults with NUT rearrangement, NMC, NUT carcinoma, carcinoma with t(15;19)(q13;p13.1) translocation, nuclear protein in testis midline carcinoma
- Open Targets
Drugs11
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ZEN-3694 | CHEMBL6068600 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| CARBOPLATIN | CHEMBL1351 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ETOPOSIDE | CHEMBL44657 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ETOPOSIDE PHOSPHATE | CHEMBL1200645 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MOLIBRESIB BESYLATE | CHEMBL4297217 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PACLITAXEL | CHEMBL428647 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MOLIBRESIB | CHEMBL1232461 | Small molecule | Phase 1 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ABEMACICLIB | CHEMBL3301610 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| AMREDOBRESIB | CHEMBL3919831 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 11
See all 11 drugsTargets23
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| BRD2 | Bromodomain and extra-terminal motif (BET) | 2 | Bromodomain and extra-terminal motif (BET) inhibitor | Phase 1 | https://conductscience.org/library/genes/6046 | Drugs and targets |
| BRD3 | Bromodomain and extra-terminal motif (BET) | 2 | Bromodomain and extra-terminal motif (BET) inhibitor | Phase 1 | https://conductscience.org/library/genes/8019 | Drugs and targets |
| BRD4 | Bromodomain and extra-terminal motif (BET) | 2 | Bromodomain and extra-terminal motif (BET) inhibitor | Phase 1 | https://conductscience.org/library/genes/23476 | Drugs and targets |
| BRDT | Bromodomain and extra-terminal motif (BET) | 2 | Bromodomain and extra-terminal motif (BET) inhibitor | Phase 1 | https://conductscience.org/library/genes/676 | Drugs and targets |
| TOP2A | DNA topoisomerase 2-alpha | 2 | DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor | Phase 1/2 | https://conductscience.org/library/genes/7153 | Drugs and targets |
| CDK4 | Cyclin-dependent kinase 4 | 1 | Cyclin-dependent kinase 4 inhibitor | Phase 1 | https://conductscience.org/library/genes/1019 | Drugs and targets |
| CDK6 | Cyclin-dependent kinase 6 | 1 | Cyclin-dependent kinase 6 inhibitor | Phase 1 | https://conductscience.org/library/genes/1021 | Drugs and targets |
| TOP2B | DNA topoisomerase II | 1 | DNA topoisomerase II inhibitor | Phase 1/2 | https://conductscience.org/library/genes/7155 | Drugs and targets |
| TUBA1A | Tubulin | 1 | Tubulin inhibitor | Phase 1/2 | https://conductscience.org/library/genes/7846 | Drugs and targets |
| TUBA1B | Tubulin | 1 | Tubulin inhibitor | Phase 1/2 | https://conductscience.org/library/genes/10376 | Drugs and targets |
1 to 10 of 23
See all 23 targetsTrials7
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01587703 | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers | Phase 1 | 196 | 2020-03-16 | Carcinoma, Midline | MOLIBRESIB | Its record names the disease | ClinicalTrials.gov |
| NCT02516553 | BI 894999 First in Human Dose Finding Study in Advanced Malignancies | Phase 1 | 174 | 2024-04-15 | Neoplasms, NUT Carcinoma | AMREDOBRESIB | Its record names the disease | ClinicalTrials.gov |
| NCT02698176 | A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006) | Phase 1 | 13 | 2018-11-05 | NUT Midline Carcinoma (NMC), Triple Negative Breast Cancer (TNBC), Non-small Cell Lung Cancer (NSCLC), Castration-resistant Prostate Cancer (CRPC) | BIRABRESIB | Its record names the disease | ClinicalTrials.gov |
| NCT05372640 | Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors | Phase 1 | 45 | Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic NUT Carcinoma, Unresectable Breast Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable NUT Carcinoma | ABEMACICLIB, ZEN-3694 | Its record names the disease | ClinicalTrials.gov | |
| NCT05019716 | Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma | Phase 1/2 | 36 | Advanced NUT Carcinoma, Metastatic NUT Carcinoma, Unresectable NUT Carcinoma | CARBOPLATIN, CISPLATIN, ETOPOSIDE, PACLITAXEL, ZEN-3694 | Its record names the disease | ClinicalTrials.gov | |
| NCT04116359 | Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma | Phase 1/2 | 0 | Metastatic NUT Carcinoma, Unresectable NUT Carcinoma | CISPLATIN, ETOPOSIDE PHOSPHATE, MOLIBRESIB BESYLATE | Its record names the disease | ClinicalTrials.gov | |
| NCT03702036 | Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma | Solid Tumours | MOLIBRESIB | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials3
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| 80mg Amor+6mg Iso/80mg Bes+6mg Iso/30mg Bes+6mg Iso/80mg Bes vs 80mg Bes+6mg Iso/80mg Amor+6mg Iso/30mg Bes+6mg Iso/80mg Bes: Number of Participants With PSA50 Response-Besylate Sub-study | 0 of 5 | 0 of 5 | 10 | NCT01587703 | Trial comparisons |
| 80mg Amor+6mg Iso/80mg Bes+6mg Iso/30mg Bes+6mg Iso/80mg Bes vs 80mg Bes+6mg Iso/80mg Amor+6mg Iso/30mg Bes+6mg Iso/80mg Bes: Number of Participants With Dose Reductions or Delays-Besylate Sub-study | 3 of 5 | 1 of 5 | 10 | NCT01587703 | Trial comparisons |
| 80mg Amor+6mg Iso/80mg Bes+6mg Iso/30mg Bes+6mg Iso/80mg Bes vs 80mg Bes+6mg Iso/80mg Amor+6mg Iso/30mg Bes+6mg Iso/80mg Bes: Number of Participants Withdrawn Due to Toxicities-Besylate Sub-study | 0 of 5 | 0 of 5 | 10 | NCT01587703 | Trial comparisons |
Papers from its trials5
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005563
GET https://conductscience.org/api/diseases/v1/MONDO_0005563/targets?page=2